Literature DB >> 15180777

Neurological soft signs discriminating mood disorders from first episode schizophrenia.

M P M Boks1, P F Liddle, J G M Burgerhof, R Knegtering, R-J van den Bosch.   

Abstract

OBJECTIVE: To investigate the specificity of neurological soft signs (NSS) for first episode schizophrenia compared with mood disorders.
METHOD: We assessed NSS in a sample of 60 healthy controls, 191 first episode psychosis patients and 81 mood disorder patients. We used a principle component analysis to identify dimensions of NSS. We subsequently investigated the specificity of these dimensions for schizophrenia and their relationships with medication and symptom scores.
RESULTS: We identified five dimensions; coordination disorders, movement disorders, increased reflexes, dyskinesia and catatonia. These dimensions were related to neural circuits associated with schizophrenia and mood disorders and included the fronto-striatal-thalamic and the fronto-cerebellar pathway. The movement disorder dimension, which was suggestive for the involvement of the fronto-striatal-thalamic pathway, was specific for first episode schizophrenia independent from medication.
CONCLUSION: NSS are the result of circuitry dysfunctions rather than overall dysfunction and a particular set of NSS shows specificity for schizophrenia. Copyright Blackwell Munksgaard 2004.

Entities:  

Mesh:

Year:  2004        PMID: 15180777     DOI: 10.1111/j.1600-0447.2004.00298.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  20 in total

1.  Reflexes in psychiatry.

Authors:  Richard D Sanders; Paulette Marie Gillig
Journal:  Innov Clin Neurosci       Date:  2011-04

2.  Motor examinations in psychiatry.

Authors:  Richard D Sander
Journal:  Psychiatry (Edgmont)       Date:  2010-11

3.  Neurological soft signs are not "soft" in brain structure and functional networks: evidence from ALE meta-analysis.

Authors:  Qing Zhao; Zhi Li; Jia Huang; Chao Yan; Paola Dazzan; Christos Pantelis; Eric F C Cheung; Simon S Y Lui; Raymond C K Chan
Journal:  Schizophr Bull       Date:  2013-05-13       Impact factor: 9.306

Review 4.  Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder.

Authors:  C Mehler-Wex; P Riederer; M Gerlach
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

Review 5.  Motor Abnormalities: From Neurodevelopmental to Neurodegenerative Through "Functional" (Neuro)Psychiatric Disorders.

Authors:  Victor Peralta; Manuel J Cuesta
Journal:  Schizophr Bull       Date:  2017-09-01       Impact factor: 9.306

6.  Clinical Utility and Lifespan Profiling of Neurological Soft Signs in Schizophrenia Spectrum Disorders.

Authors:  Raymond C K Chan; Weizhen Xie; Fu-lei Geng; Ya Wang; Simon S Y Lui; Chuan-yue Wang; Xin Yu; Eric F C Cheung; Robert Rosenthal
Journal:  Schizophr Bull       Date:  2015-12-28       Impact factor: 9.306

7.  Striatal abnormalities and spontaneous dyskinesias in non-clinical psychosis.

Authors:  Vijay A Mittal; Joseph M Orr; Jessica A Turner; Andrea L Pelletier; Derek J Dean; Jessica Lunsford-Avery; Tina Gupta
Journal:  Schizophr Res       Date:  2013-10-22       Impact factor: 4.939

8.  Neurological soft signs and cognitive functions: Amongst euthymic bipolar I disorder cases, non-affected first degree relatives and healthy controls.

Authors:  Srikant Sharma; Triptish Bhatia; Sati Mazumdar; Smita N Deshpande
Journal:  Asian J Psychiatr       Date:  2016-04-23

9.  Childhood motor coordination and adult schizophrenia spectrum disorders.

Authors:  Jason Schiffman; Holger J Sorensen; Justin Maeda; Erik L Mortensen; Jeff Victoroff; Kentaro Hayashi; Niels M Michelsen; Morten Ekstrom; Sarnoff Mednick
Journal:  Am J Psychiatry       Date:  2009-07-15       Impact factor: 18.112

10.  Neurological soft signs in schizophrenia: a meta-analysis.

Authors:  Raymond C K Chan; Ting Xu; R Walter Heinrichs; Yue Yu; Ya Wang
Journal:  Schizophr Bull       Date:  2009-04-17       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.